The RASD2 antibody targets the RASD2 protein, a member of the RAS superfamily of small GTPases. RASD2. also known as Rhes or Ric, is encoded by the RASD2 gene located on human chromosome 22q13.1. Unlike classical RAS proteins, RASD2 lacks intrinsic GTPase activity and functions as a constitutively active GTP-binding protein. It is highly expressed in the striatum and other brain regions, where it modulates dopamine signaling, mTOR pathways, and neuronal survival. RASD2 interacts with G-protein-coupled receptors (GPCRs) and influences autophagy, synaptic plasticity, and neurodevelopment. Dysregulation of RASD2 has been implicated in neuropsychiatric disorders (e.g., Huntington’s disease, schizophrenia), metabolic syndromes, and cancers. Antibodies against RASD2 are widely used in Western blotting, immunohistochemistry, and immunofluorescence to study its tissue-specific expression, subcellular localization, and interactions in disease models. These tools have been critical in elucidating RASD2’s dual role in promoting cell survival under stress while contributing to pathological aggregation in neurodegenerative conditions. Recent studies also highlight its potential involvement in cancer progression through Akt and Wnt/β-catenin signaling. Validated RASD2 antibodies typically recognize epitopes within its conserved GTP-binding domain (aa 10-180) or C-terminal region (aa 200-268).